Protection against RSV derived from preF IgG antibodies waned 6 months after infection in an analysis of patients with confirmed disease and household contacts.

RSV seasons ended earlier than usual in 2022-23 and 2023-24, and typical human hMPV circulation patterns have returned since the COVID-19 pandemic.

An outside group of experts agreed that the CDC should recommend a new antibody drug that offers protection against RSV for ...